- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01574339
Effect of Long-Term Electrical Stimulation on LES Pressure and Esophageal Acid Exposure in Patients With GERD
An Investigation of the Effect of Long-Term Electrical Stimulation on Lower Esophageal Sphincter (LES) Pressure and Esophageal Acid Exposure in Patients With Gastroesophageal Reflux Disease (GERD)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
EndoStim has developed an investigational medical device specifically designed to deliver electrical stimulation to the LES and has completed two clinical feasibility studies using an external version of the EndoStim stimulation system in fifteen subjects. In these two short-term studies, electrical stimulation resulted in significant increases in LES pressure.
This study will further evaluate the safety of the procedure and its feasibility for use in this group of patients.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Santiago, Chile
- Hospital Clínico de la Pontificia Universidad Católica de Chile
-
-
-
-
-
Bogota, Colombia
- San Ignacio
-
-
-
-
-
Hyderabad, India, 500082
- Asian Institute of Gastroenterology
-
-
-
-
-
Mexico City, Mexico
- . Zalvador Zubiran National Institute of Medical Science and Nutrition
-
-
-
-
-
Amsterdam, Netherlands, 1105
- AMC Amsterdam
-
Maastricht, Netherlands
- UMC Maastrcht
-
Utrecht, Netherlands, 3508
- UMC Utrecht
-
-
-
-
Takapuna
-
Aukland, Takapuna, New Zealand
- North Shore Hospital
-
-
-
-
-
London, United Kingdom
- St. Thomas Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subject is between 21 - 70 years of age.
- Subject has a history of heartburn, regurgitation or both for > 12 month prompting physician recommendation of continual daily use of PPI before study entry.
- Baseline GERD HRQL heartburn score following 10-14 days off PPI which is ≥ 20 and at least 10 points higher than the on PPI score
- Subject who are on standard medical therapy for 12 months or longer and experience discomfort or who are otherwise dissatisfied with GERD symptoms
- Subjects with a GERD condition that in the opinion of the PI justifies a minimally invasive reversible procedure prior to attempting anatomical change such as Nissen fundoplication
- Subject has an American Society of Anesthesiologists (ASA) Physical Status Classification I or II (or comparable local classification if any).
- Subject has exhibited excessive lower esophageal acid exposure during 24-hour pHmetry of antisecretory therapy performed within 6 months of screening visit; pH < 4 for > 5% of total time.
- Subject has a resting LES end expiratory pressure > 5mm Hg and < 15 mm Hg on a high resolution manometry within 6 months of enrollment.
- Subject has esophagitis ≤ Grade C (LA classification) on upper endoscopy within 6 months of enrollment.
- Subject has esophageal body contraction amplitude > 30 mmHg for > 50% of swallows and > 50% peristaltic contractions on high resolution manometry.
- Subject has signed the informed consent form and is able to adhere to study visit schedule.
Exclusion Criteria:
- Subject has any non-GERD esophageal motility disorders.
- Subject has gastroparesis.
- Subject has any significant multisystem diseases.
- Subject has an autoimmune or a connective tissue disorder (e.g. scleroderma, dermatomyositis, Calcinosis-Raynaud's-Esophagus, Sclerodactyly Syndrome (CREST), Sjogren's Syndrome, Sharp's Syndrome), requiring therapy in the preceding 2 years.
- Subject has Barrett's epithelium (> M2; > C1) or any grade of dysplasia.
- Subject has a hiatal hernia larger than 3 cm.
- Subject has a body mass index (BMI) greater than 35 kg/m2.
- Subject has Type 1 diabetes mellitus
- Subject has uncontrolled Type 2 diabetes mellitus (T2DM) defined as HbA1c > 9.5 in the previous 6 months, or has T2DM for > 10 years.
- Subject has a history of suspected or confirmed esophageal or gastric cancer.
- Subject has esophageal or gastric varices.
- Subject has significant cardiac arrhythmia or ectopy or significant cardiovascular disease.
- Subject has an existing implanted electrical stimulator (e.g., pacemaker, AICD).
- Subject requires chronic anticoagulant therapy.
- Subject has dysphagia or esophageal peptic stricture, excluding Schatzki's ring.
- Subject of child-bearing potential who is pregnant or intends to become pregnant during the trial period.
- Subject is currently enrolled in other potentially confounding research.
- History of any malignancy in the last 2 years. History of previous esophageal or gastric surgery, including nissen fundoplication.
- Subject has any condition that, at the discretion of the investigator or sponsor, would preclude participation in the trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment Arm
|
The EndoStim LES Stimulation System comprises three components: an electrical stimulation lead, an implantable pulse generator (IPG) and an external programmer. The IPG and stimulation lead are to be implanted within the subject's body using conventional laparoscopy. The device programmer is to be used by the study investigator and/or a company technical representative. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Primary Safety Endpoint
Time Frame: 6 months follow-up
|
Safety will be assessed by incidence and severity of adverse events through 6 months follow-up.
Included in this assessment will be the proportion of subjects with any of the following outcomes between device implant and completion of the month 6 evaluation: (1) death, or (2) medical morbidity associated with the device and/or implantation procedure.
|
6 months follow-up
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Secondary Efficacy Endpoints
Time Frame: 6 months follow-up
|
Change in patient's GERD-HRQL from baseline to 6 months.
|
6 months follow-up
|
Secondary Efficacy Endpoints
Time Frame: 6 months follow-up
|
Baseline pH values of % 24-hour esophageal pH< 4.0, and number of reflux events >1minute and >5 minute duration with the same on-stimulation pH parameters at 6 months.
|
6 months follow-up
|
Secondary Efficacy Endpoints
Time Frame: 6 months follow-up
|
Change in symptoms frequency and severity at 6 months Vs.
baseline as measured by patient symptom diary and patients quality of life measured by SF- 12.
|
6 months follow-up
|
Secondary Efficacy Endpoints
Time Frame: 6 months follow-up
|
Change in antisecretory medication use as evaluated during the two weeks prior to the month 6 follow up compared to baseline.
|
6 months follow-up
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: A. J. Bredenoord, Dr. med., Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- Principal Investigator: T. Horbach, PD. Dr. med., Stadtkrankenhaus Schwabach, Schwabach, Germany
- Principal Investigator: A. Escalona, Dr. med., Hospital Clínico de la Pontificia Universidad Católica de Chile, Santiago, Chile
- Principal Investigator: Nageshwar Reddy, M.D.,, Asian Institute of Gastroenterology
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CS005
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gastroesophageal Reflux Disease
-
TakedaTerminatedGastroesophageal Reflux Disease | Non-erosive Reflux DiseaseSwitzerland, Netherlands
-
Vanderbilt University Medical CenterCompletedGastroesophageal Reflux Disease (GERD) | Non-erosive Reflux Disease (NERD)United States
-
Mansoura UniversityWithdrawnGastroesophageal Reflux Disease
-
Cliniques universitaires Saint-Luc- Université...UnknownGastroesophageal Reflux DiseaseBelgium
-
GlaxoSmithKlineCompletedReflux, Gastroesophageal | Gastroesophageal Reflux DiseaseAustralia
-
King Chulalongkorn Memorial HospitalCompleted
-
PfizerTerminatedGastroesophageal Reflux DiseaseBrazil, Germany, Korea, Republic of, Belgium, Spain, Slovakia, France
-
University of North Carolina, Chapel HillNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedGastroesophageal Reflux Disease | GERD | Acid Reflux | RefluxUnited States
-
GlaxoSmithKlineCompletedReflux, Gastroesophageal | Gastroesophageal Reflux DiseaseAustralia
-
Scandinavia PharmaRecruitingGastroesophageal Reflux DiseaseColombia
Clinical Trials on EndoStim LES Stimulation System
-
EndoStim Inc.Completed
-
EndoStim Inc.TerminatedGERDDenmark, Netherlands, Germany, Austria, United Kingdom, Argentina, Mexico
-
Maastricht University Medical CenterEndoStim Inc.UnknownGERD | Sleeve GastrectomyNetherlands
-
EndoStim Inc.TerminatedGastroesophageal Reflux | Reflux, Gastroesophageal | Gastroesophageal Reflux Disease (GERD) | Acid RefluxUnited States, Belgium, Netherlands, United Kingdom
-
Erasme University HospitalEndoStim Inc.Terminated
-
Military University Hospital, PragueRecruiting
-
Montefiore Medical CenterAlbert Einstein College of MedicineTerminated
-
Mainstay MedicalActive, not recruitingChronic Low Back PainUnited States, Belgium, United Kingdom, Netherlands, Australia
-
Abbott Medical DevicesTerminatedDepressive Disorder, Major | Unipolar DepressionUnited States, Canada, United Kingdom
-
Clarity Health Technologies, IncSymmetryScience Group, Inc.RecruitingAlzheimer Disease | Healthy AgingUnited States